Abstract
Background:
The appropriate duration of dual-antiplatelet therapy (DAPT) after drug-eluting stent (DES) placement remains controversial.
Purpose:
To summarize data on clinical outcomes with longer- versus shorter-duration DAPT after DES placement in adults with coronary artery disease.
Data Sources:
Ovid MEDLINE and EMBASE, 1996 to 27 March 2015, and manual screening of references.
Study Selection:
Randomized, controlled trials comparing longer- versus shorter-duration DAPT after DES placement.
Data Extraction:
Two reviewers screened potentially eligible articles; extracted data on populations, interventions, and outcomes; assessed risk of bias; and used the Grading of Recommendations Assessment, Development and Evaluation guidelines to rate overall confidence in effect estimates.
Data Synthesis:
Among 1010 articles identified, 9 trials including 29 531 patients were eligible; data were complete for 28 808 patients. Moderate-quality evidence showed that longer-duration DAPT decreased risk for myocardial infarction (risk ratio [RR], 0.73 [95% CI, 0.58 to 0.92]) and increased mortality (RR, 1.19 [CI, 1.04 to 1.36]). High-quality evidence showed that DAPT increased risk for major bleeding (RR, 1.63 [CI, 1.34 to 1.99]).
Limitation:
Confidence in estimates were decreased owing to imprecision for most outcomes (particularly myocardial infarction), risk of bias from limited blinding in 7 of 9 studies, indirectness due to variability in use of first- and second-generation stents, and off-protocol use of DAPT in some studies.
Conclusion:
Extended DAPT is associated with approximately 8 fewer myocardial infarctions per 1000 treated patients per year but 6 more major bleeding events than shorter-duration DAPT. Because absolute effects are very small and closely balanced, decisions regarding the duration of DAPT therapy must take into account patients' values and preference.
Primary Funding Source:
None.
References
- 1.
Fajadet J ,Wijns W ,Laarman GJ ,Kuck KH ,Ormiston J ,Münzel T ,et al ;ENDEAVOR II Investigators . Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation. 2006;114:798-806. [PMID: 16908773] CrossrefMedlineGoogle Scholar - 2.
Moses JW ,Leon MB ,Popma JJ ,Fitzgerald PJ ,Holmes DR ,O'Shaughnessy C ,et al ;SIRIUS Investigators . Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-23. [PMID: 14523139] CrossrefMedlineGoogle Scholar - 3.
Stone GW ,Ellis SG ,Cox DA ,Hermiller J ,O'Shaughnessy C ,Mann JT ,et al ;TAXUS-IV Investigators . A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350:221-31. [PMID: 14724301] CrossrefMedlineGoogle Scholar - 4.
Windecker S ,Kolh P ,Alfonso F ,Collet JP ,Cremer J ,Falk V ,et al ;Authors/Task Force members . 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541-619. [PMID: 25173339] doi:10.1093/eurheartj/ehu278 CrossrefMedlineGoogle Scholar - 5.
Levine GN ,Bates ER ,Blankenship JC ,Bailey SR ,Bittl JA ,Cercek B ,et al . 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-651. [PMID: 22064601] doi:10.1161/CIR.0b013e31823ba622 CrossrefMedlineGoogle Scholar - 6.
Vandvik PO ,Lincoff AM ,Gore JM ,Gutterman DD ,Sonnenberg FA ,Alonso-Coello P ,et al ;American College of Chest Physicians . Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e637S-68S. [PMID: 22315274] doi:10.1378/chest.11-2306 CrossrefMedlineGoogle Scholar - 7.
Daemen J ,Wenaweser P ,Tsuchida K ,Abrecht L ,Vaina S ,Morger C ,et al . Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78. [PMID: 17321312] CrossrefMedlineGoogle Scholar - 8.
Eisenstein EL ,Anstrom KJ ,Kong DF ,Shaw LK ,Tuttle RH ,Mark DB ,et al . Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-68. [PMID: 17148711] CrossrefMedlineGoogle Scholar - 9.
Pfisterer M ,Brunner-LaRocca HP ,Buser PT ,Rickenbacher P ,Hunziker P ,Mueller C ,et al ;BASKET-LATE Investigators . Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91. [PMID: 17174201] CrossrefMedlineGoogle Scholar - 10.
Faxon DP ,Lawler E ,Young M ,Gaziano M ,Kinlay S . Prolonged clopidogrel use after bare metal and drug-eluting stent placement: the Veterans Administration drug-eluting stent study. Circ Cardiovasc Interv. 2012;5:372-80. [PMID: 22668555] doi:10.1161/CIRCINTERVENTIONS.111.967257 CrossrefMedlineGoogle Scholar - 11.
Collet JP ,Silvain J ,Barthélémy O ,Rangé G ,Cayla G ,VanBelle E ,et al ;ARCTIC investigators . Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384:1577-85. [PMID: 25037988] doi:10.1016/S0140-6736(14)60612-7 CrossrefMedlineGoogle Scholar - 12.
Feres F ,Costa RA ,Abizaid A ,Leon MB ,Marin-Neto JA ,Botelho RV ,et al ;OPTIMIZE Trial Investigators . Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-22. [PMID: 24177257] doi:10.1001/jama.2013.282183 CrossrefMedlineGoogle Scholar - 13.
Gwon HC ,Hahn JY ,Park KW ,Song YB ,Chae IH ,Lim DS ,et al . Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-13. [PMID: 22179532] doi:10.1161/CIRCULATIONAHA.111.059022 CrossrefMedlineGoogle Scholar - 14.
Lee CW ,Ahn JM ,Park DW ,Kang SJ ,Lee SW ,Kim YH ,et al . Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-12. [PMID: 24097439] doi:10.1161/CIRCULATIONAHA.113.003303 CrossrefMedlineGoogle Scholar - 15.
Park SJ ,Park DW ,Kim YH ,Kang SJ ,Lee SW ,Lee CW ,et al . Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-82. [PMID: 20231231] doi:10.1056/NEJMoa1001266 CrossrefMedlineGoogle Scholar - 16.
Valgimigli M ,Borghesi M ,Tebaldi M ,Vranckx P ,Parrinello G ,Ferrari R ;PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY Investigators . Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY). Eur Heart J. 2013;34:909-19. [PMID: 23315904] doi:10.1093/eurheartj/ehs460 CrossrefMedlineGoogle Scholar - 17.
Mauri L ,Kereiakes DJ ,Yeh RW ,Driscoll-Shempp P ,Cutlip DE ,Steg PG ,et al ;DAPT Study Investigators . Twelve or 30 monthsj of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66. [PMID: 25399658] doi:10.1056/NEJMoa1409312 CrossrefMedlineGoogle Scholar - 18.
Ferreira-González I ,Busse JW ,Heels-Ansdell D ,Montori VM ,Akl EA ,Bryant DM ,et al . Problems with use of composite end points in cardiovascular trials: systematic review of randomised controlled trials. BMJ. 2007;334:786. [PMID: 17403713] CrossrefMedlineGoogle Scholar - 19.
Lim E ,Brown A ,Helmy A ,Mussa S ,Altman DG . Composite outcomes in cardiovascular research: a survey of randomized trials. Ann Intern Med. 2008;149:612-7. [PMID: 18981486] LinkGoogle Scholar - 20.
Higgins JP ,Altman DG ,Gøtzsche PC ,Jüni P ,Moher D ,Oxman AD ,et al ;Cochrane Bias Methods Group . The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217] doi:10.1136/bmj.d5928 CrossrefMedlineGoogle Scholar - 21.
Guyatt GH ,Oxman AD ,Vist GE ,Kunz R ,Falck-Ytter Y ,Alonso-Coello P ,et al ;GRADE Working Group . GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6. [PMID: 18436948] doi:10.1136/bmj.39489.470347.AD CrossrefMedlineGoogle Scholar - 22.
Guyatt GH ,Oxman AD ,Vist G ,Kunz R ,Brozek J ,Alonso-Coello P ,et al . GRADE guidelines: 4. Rating the quality of evidence—study limitations (risk of bias). J Clin Epidemiol. 2011;64:407-15. [PMID: 21247734] doi:10.1016/j.jclinepi.2010.07.017 CrossrefMedlineGoogle Scholar - 23.
Guyatt GH ,Oxman AD ,Kunz R ,Brozek J ,Alonso-Coello P ,Rind D ,et al . GRADE guidelines 6. Rating the quality of evidence—imprecision. J Clin Epidemiol. 2011;64:1283-93. [PMID: 21839614] doi:10.1016/j.jclinepi.2011.01.012 CrossrefMedlineGoogle Scholar - 24.
Guyatt GH ,Oxman AD ,Kunz R ,Woodcock J ,Brozek J ,Helfand M ,et al ;GRADE Working Group . GRADE guidelines: 7. Rating the quality of evidence—inconsistency. J Clin Epidemiol. 2011;64:1294-302. [PMID: 21803546] doi:10.1016/j.jclinepi.2011.03.017 CrossrefMedlineGoogle Scholar - 25.
Guyatt GH ,Oxman AD ,Kunz R ,Woodcock J ,Brozek J ,Helfand M ,et al ;GRADE Working Group . GRADE guidelines: 8. Rating the quality of evidence—indirectness. J Clin Epidemiol. 2011;64:1303-10. [PMID: 21802903] doi:10.1016/j.jclinepi.2011.04.014 CrossrefMedlineGoogle Scholar - 26.
Guyatt GH ,Oxman AD ,Montori V ,Vist G ,Kunz R ,Brozek J ,et al . GRADE guidelines: 5. Rating the quality of evidence—publication bias. J Clin Epidemiol. 2011;64:1277-82. [PMID: 21802904] doi:10.1016/j.jclinepi.2011.01.011 CrossrefMedlineGoogle Scholar - 27.
Akl EA ,Johnston BC ,Alonso-Coello P ,Neumann I ,Ebrahim S ,Briel M ,et al . Addressing dichotomous data for participants excluded from trial analysis: a guide for systematic reviewers. PLoS One. 2013;8:e57132. [PMID: 23451162] doi:10.1371/journal.pone.0057132 CrossrefMedlineGoogle Scholar - 28.
Akl EA ,Briel M ,You JJ ,Sun X ,Johnston BC ,Busse JW ,et al . Potential impact on estimated treatment effects of information lost to follow-up in randomised controlled trials (LOST-IT): systematic review. BMJ. 2012;344:e2809. [PMID: 22611167] doi:10.1136/bmj.e2809 CrossrefMedlineGoogle Scholar - 29.
Kim BK ,Hong MK ,Shin DH ,Nam CM ,Kim JS ,Ko YG ,et al ;RESET Investigators . A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340-8. [PMID: 22999717] doi:10.1016/j.jacc.2012.06.043 CrossrefMedlineGoogle Scholar - 30.
Gilard M ,Barragan P ,Noryani AA ,Noor HA ,Majwal T ,Hovasse T ,et al . 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol. 2015;65:777-86. [PMID: 25461690] doi:10.1016/j.jacc.2014.11.008 CrossrefMedlineGoogle Scholar - 31.
Borenstein MH ,Hedges LV ,Higgins JPT ,Rothstein HR . Introduction to Meta-analysis. Chichester, United Kingdom: J Wiley; 2008. Google Scholar - 32.
IntHout J ,Ioannidis JP ,Borm GF . The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method. BMC Med Res Methodol. 2014;14:25. [PMID: 24548571] doi:10.1186/1471-2288-14-25 CrossrefMedlineGoogle Scholar - 33.
Colombo A ,Chieffo A ,Frasheri A ,Garbo R ,Masotti-Centol M ,Salvatella N ,et al . Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-97. [PMID: 25236346] doi:10.1016/j.jacc.2014.09.008 CrossrefMedlineGoogle Scholar - 34.
Schulz-Schüpke S ,Byrne RA ,Ten Berg JM ,Neumann FJ ,Han Y ,Adriaenssens T ,et al ;on behalf of the Intracoronary Stenting and Antithrombotic Regimen: Safety And EFficacy of 6 Months Dual Antiplatelet Therapy After Drug-Eluting Stenting (ISAR-SAFE) trial investigators. . ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 versus 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015. [PMID: 25616646] CrossrefMedlineGoogle Scholar - 35.
Kirtane AJ ,Gupta A ,Iyengar S ,Moses JW ,Leon MB ,Applegate R ,et al . Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119:3198-206. [PMID: 19528338] doi:10.1161/CIRCULATIONAHA.108.826479 CrossrefMedlineGoogle Scholar - 36.
Kirtane AJ ,Leon MB ,Ball MW ,Bajwa HS ,Sketch MH ,Coleman PS ,et al ;ENDEAVOR IV Investigators . The "final" 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent. JACC Cardiovasc Interv. 2013;6:325-33. [PMID: 23523453] doi:10.1016/j.jcin.2012.12.123 CrossrefMedlineGoogle Scholar - 37.
Stone GW ,Rizvi A ,Newman W ,Mastali K ,Wang JC ,Caputo R ,et al ;SPIRIT IV Investigators . Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med. 2010;362:1663-74. [PMID: 20445180] doi:10.1056/NEJMoa0910496 CrossrefMedlineGoogle Scholar - 38.
Palmerini T ,Benedetto U ,Bacchi-Reggiani L ,Riva DD ,Biondi-Zoccai G ,Feres F ,et al . Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015. [PMID: 25777667] doi:10.1016/S0140-6736(15)60263-X CrossrefMedlineGoogle Scholar
Author, Article, and Disclosure Information
Frederick A. Spencer,
From McMaster University, Hamilton, Ontario, Canada; Pt. Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Rohtak, Haryana, India; and Innlandet Hospital Trust, Gjøvik, Norway.
Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M15-0083.
Editors' Disclosures: Christine Laine, MD, MPH, Editor in Chief, reports that she has no financial relationships or interests to disclose. Darren B. Taichman, MD, PhD, Executive Deputy Editor, reports that he has no financial relationships or interests to disclose. Cynthia D. Mulrow, MD, MSc, Senior Deputy Editor, reports that she has no relationships or interests to disclose. Deborah Cotton, MD, MPH, Deputy Editor, reports that she has no financial relationships or interest to disclose. Jaya K. Rao, MD, MHS, Deputy Editor, reports that she has stock holdings/options in Eli Lilly and Pfizer. Sankey V. Williams, MD, Deputy Editor, reports that he has no financial relationships or interests to disclose. Catharine B. Stack, PhD, MS, Deputy Editor for Statistics, reports that she has stock holdings in Pfizer.
Corresponding Author: Frederick A. Spencer, MD, Department of Medicine, McMaster University, Faculty of Health Sciences, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada; e-mail, fspence@mcmaster.
Current Author Addresses: Dr. Spencer and Mr. Chetan: Department of Medicine, McMaster University, Faculty of Health Sciences, 50 Charlton Avenue East, Hamilton, Ontario L8N 4A6, Canada.
Dr. Prasad: Department of Community Medicine, Pt. Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences, Medical Road, Maharishi Dayanand University, Rohtak, Haryana 124001, India.
Dr. Vandvik: Norwegian Knowledge Centre for the Health Services (The Knowledge Centre), PO Box 7004, St. Olavs Plass, N-0130 Oslo, Norway.
Drs. Zhou and Guyatt: Department of Clinical Epidemiology and Biostatistics, McMaster University, 1280 Main St West, Hamilton, Ontario L8S 4L8, Canada.
Author Contributions: Conception and design: G.H. Guyatt, F.A. Spencer, P.O. Vandvik.
Analysis and interpretation of the data: D. Chetan, G.H. Guyatt, M. Prasad, F.A. Spencer, P.O. Vandvik, Q. Zhou.
Drafting of the article: F.A. Spencer, P.O. Vandvik.
Critical revision for important intellectual content: D. Chetan, G.H. Guyatt, M. Prasad, P.O. Vandvik.
Final approval of the article: D. Chetan, G.H. Guyatt, M. Prasad, F.A. Spencer, P.O. Vandvik, Q. Zhou.
Statistical expertise: Q. Zhou.
Collection and assembly of data: D. Chetan, M. Prasad, F.A. Spencer.
This article was published online first at www.annals.org on 26 May 2015.
Submit a Comment
Contributors must reveal any conflict of interest. Comments are moderated. Please see our information for authorsregarding comments on an Annals publication.
*All comments submitted after October 1, 2021 and selected for publication will be published online only.